Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Population pharmacokinetics of abacavir in infants, toddlers and children.

Zhao W, Piana C, Danhof M, Burger D, Della Pasqua O, Jacqz-Aigrain E.

Br J Clin Pharmacol. 2013 Jun;75(6):1525-35. doi: 10.1111/bcp.12024.

2.

Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor.

Idzik KR, Cywinski PJ, Cranfield CG, Mohr GJ, Beckert R.

J Fluoresc. 2011 May;21(3):1195-204. doi: 10.1007/s10895-010-0798-7. Epub 2011 Jan 11.

3.

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

Cross SJ, Rodman JH, Lindsey JC, Robbins BL, Rose CH, Yuen GJ, D'angelo LJ.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):54-9. doi: 10.1097/QAI.0b013e31819a2257.

4.

Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.

Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM, Heckman BE, Sprenger HL, Tustin NB, Rose CH, Poston PA, Neal EF, Pakes GE, Nikanjam M, Capparelli EV.

Clin Pharmacol Ther. 2009 Apr;85(4):394-401. doi: 10.1038/clpt.2008.236. Epub 2008 Dec 31.

5.

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.

Hazra R, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty JF, Yale K, Poblenz M, Kearney BP, Zhong L, Coakley DF, Blanche S, Bresson JL, Zuckerman JA, Zeichner SL.

Antimicrob Agents Chemother. 2004 Jan;48(1):124-9.

6.

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD; Adult AIDS Clinical Trials Group Protocol 368/886 Study Team.

Antimicrob Agents Chemother. 2003 Jun;47(6):1929-35.

7.

Supplemental Content

Support Center